AIM
HRMY icon

Aigen Investment Management’s Harmony Biosciences HRMY Stock Holding History

Aigen Investment Management’s Portfolio HRMY Stock Details HRMY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$225K Buy
+6,193
New +$195K 0.06% 406
2024
Q1 		– Sell
-7,375
Closed -$238K – 831
2023
Q4 		$238K Buy
+7,375
New +$206K 0.04% 594
2023
Q3 		– Sell
-8,788
Closed -$309K – 939
2023
Q2 		$309K Buy
+8,788
New +$303K 0.05% 487

Other funds holding HRMY

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
LSV Asset Management
LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Aigen Investment Management's HRMY Position: Q2 2026 in Review

Aigen Investment Management opened a new position in Harmony Biosciences (HRMY) in Q2 2026: 6,193 shares worth $225K. The stake represents 0.06% of the portfolio and ranks #406 among its holdings. This is a return to the name: Aigen Investment Management previously reported a position in HRMY as recently as Q4 2023.

Aigen Investment Management first reported a position in HRMY in Q2 2023 and has held it in 3 quarters since. The position peaked at $309K in Q2 2023. 327 funds tracked by Wall St. Rank hold HRMY as of Q2 2026.

  • Aigen Investment Management held 6,193 shares of Harmony Biosciences worth $225K as of Q2 2026.
  • Harmony Biosciences was a new Aigen Investment Management position in Q2 2026.
  • Harmony Biosciences made up 0.06% of Aigen Investment Management's portfolio in Q2 2026, its #406 holding.
  • Aigen Investment Management first reported a position in Harmony Biosciences in Q2 2023 and has held it in 3 quarters since.
  • Aigen Investment Management's Harmony Biosciences position peaked at $309K in Q2 2023.
  • 327 funds tracked by Wall St. Rank held Harmony Biosciences as of Q2 2026.

Based on Aigen Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.